The DOI matches its Crossref record; 379 of the 379 references it cites were found in a registry or an index.
Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies
Open accessAbstract
Osteosarcoma is the most common primary malignant bone tumour in children and adolescents. Due to micrometastatic spread, radical surgery alone rarely results in cure. Introduction of combination chemotherapy in the 1970s, however, dramatically increased overall survival rates from 20% to approximately 70%. Unfortunately, large clinical trials aiming to intensify treatment in the past decades have failed to achieve higher cure rates. In this review, we revisit how the heterogenous nature of osteosarcoma as well as acquired and intrinsic resistance to chemotherapy can account for stagnation in therapy improvement. We summarise current osteosarcoma treatment strategies focusing on molecular determinants of treatment susceptibility and resistance. Understanding therapy susceptibility and resistance provides a basis for rational therapy betterment for both identifying patients that might be cured with less toxic interventions and targeting resistance mechanisms to sensitise resistant osteosarcoma to conventional therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Sampson, V. B., Vetter, N. S., Zhang, W., Patil, P., Mason, R. W., George, E., Gorlick, R. G., & Kolb, E. A. (2016) · Oncotarget · doi:10.18632/oncotarget.13358 · Cited by 23
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Macrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B.-Z., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,188
The Nuclear Factor NF- B Pathway in Inflammation
Lawrence, T. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001651 · Cited by 4,898
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Self-eating and self-killing: crosstalk between autophagy and apoptosis
Maiuri, M. C., Zalckvar, E., Kimchi, A., & Kroemer, G. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2239 · Cited by 3,577
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335 · cited 1×
“This is in line with the finding that cisplatin resistance is most often a result of altered DNA repair mechanisms and not cellular depletion of the drug ([316] and see following section).”
BackgroundMacrophages as regulators of tumour immunity and immunotherapy
DeNardo, D. G., & Ruffell, B. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,528
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Auphan, N., DiDonato, J. A., Rosette, C., Helmberg, A., & Karin, M. (1995) · Science · doi:10.1126/science.270.5234.286 · Cited by 2,390
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Mirabello, L., Troisi, R. J., & Savage, S. A. (2009) · Cancer · doi:10.1002/cncr.24121 · Cited by 2,199
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
Couzin-Frankel, J. (2013) · Science · doi:10.1126/science.342.6165.1432 · Cited by 2,051
Treatment of Acute Lymphoblastic Leukemia
Pui, C.-H., & Evans, W. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052603 · Cited by 1,976
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L.-S., Lyu, Y. L., Liu, L. F., & Yeh, E. T. H. (2012) · Nature Medicine · doi:10.1038/nm.2919 · Cited by 1,948
The Different Mechanisms of Cancer Drug Resistance: A Brief Review
Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B. (2017) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2017.041 · Cited by 1,883
The Epidemiology of Osteosarcoma
Ottaviani, G., & Jaffe, N. (2009) · Cancer Treatment and Research · doi:10.1007/978-1-4419-0284-9_1 · Cited by 1,786
Muller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
Isakoff, M. S., Bielack, S. S., Meltzer, P., & Gorlick, R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4895 · Cited by 1,567
Double identity for proteins of the Bcl-2 family
Reed, J. C. (1997) · Nature · doi:10.1038/42867 · Cited by 1,475
Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452 · cited 2×
“Pembrolizumab had limited efficacy in adults [206]”
BackgroundAnti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360
The role of glutathione-S-transferase in anti-cancer drug resistance
Townsend, D. M., & Tew, K. D. (2003) · Oncogene · doi:10.1038/sj.onc.1206940 · Cited by 1,353
The ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,353
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Boussiotis, V. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1514296 · Cited by 1,339
PARP inhibition: PARP1 and beyond
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2812 · Cited by 1,298
Translational biology of osteosarcoma
Kansara, M., Teng, M. W., Smyth, M. J., & Thomas, D. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3838 · Cited by 1,294
Goel, H. L., & Mercurio, A. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3627 · Cited by 1,253
Link, M. P., Goorin, A. M., Miser, A. W., Green, A. A., Pratt, C. B., Belasco, J. B., Pritchard, J., Malpas, J. S., Baker, A. R., Kirkpatrick, J. A., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142502 · Cited by 1,204
Trophic macrophages in development and disease
Pollard, J. W. (2009) · Nature Reviews Immunology · doi:10.1038/nri2528 · Cited by 1,178
Mulrooney, D. A., Yeazel, M. W., Kawashima, T., Mertens, A. C., Mitby, P., Stovall, M., Donaldson, S. S., Green, D. M., Sklar, C. A., Robison, L. L., et al. (2009) · BMJ · doi:10.1136/bmj.b4606 · Cited by 1,166
Rosen, G., Caparros, B., Huvos, A. G., Kosloff, C., Nirenberg, A., Cacavio, A., Marcove, R. C., Lane, J. M., Mehta, B., & Urban, C. (1982) · Cancer · doi:10.1002/1097-0142(19820315)49:6<1221::aid-cncr2820490625>3.0.co;2-e · Cited by 1,090
Molecular targeted therapy: Treating cancer with specificity
Lee, Y. T., Tan, Y. J., & Oon, C. E. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.07.034 · Cited by 1,067
Arnold, M., Rutherford, M. J., Bardot, A., Ferlay, J., Andersson, T. M.-L., Myklebust, T. Å., Tervonen, H., Thursfield, V., Ransom, D., Shack, L., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30456-5 · Cited by 1,063
Molecular cloning of a new transforming gene from a chemically transformed human cell line
Cooper, C. S., Park, M., Blair, D. G., Tainsky, M. A., Huebner, K., Croce, C. M., & Vande Woude, G. F. (1984) · Nature · doi:10.1038/311029a0 · Cited by 989
Anthracycline Chemotherapy and Cardiotoxicity
McGowan, J. V., Chung, R., Maulik, A., Piotrowska, I., Walker, J. M., & Yellon, D. M. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6711-0 · Cited by 956
Etoposide: four decades of development of a topoisomerase II inhibitor
Hande, K. R. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00228-7 · Cited by 949
Kager, L., Zoubek, A., Pötschger, U., Kastner, U., Flege, S., Kempf-Bielack, B., Branscheid, D., Kotz, R., Salzer-Kuntschik, M., Winkelmann, W., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.132 · Cited by 934
Krummel, M. F., & Allison, J. P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.6.2533 · Cited by 932
Swain, S. M., Miles, D., Kim, S.-B., Im, Y.-H., Im, S.-A., Semiglazov, V., Ciruelos, E., Schneeweiss, A., Loi, S., Monturus, E., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30863-0 · Cited by 922
Survivors of childhood and adolescent cancer: life-long risks and responsibilities
Robison, L. L., & Hudson, M. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3634 · Cited by 857
Glutathione-Associated Enzymes In Anticancer Drug Resistance
Tew, K. D. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3143 · Cited by 856
The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux
Synold, T. W., Dussault, I., & Forman, B. M. (2001) · Nature Medicine · doi:10.1038/87912 · Cited by 840
Nucleotide Excision Repair in Eukaryotes
Scharer, O. D. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012609 · Cited by 801
Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.14.0095 · Cited by 752
Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma
Chen, X., Bahrami, A., Pappo, A., Easton, J., Dalton, J., Hedlund, E., Ellison, D., Shurtleff, S., Wu, G., Wei, L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.003 · Cited by 752
Chen, Z., Shi, T., Zhang, L., Zhu, P., Deng, M., Huang, C., Hu, T., Jiang, L., & Li, J. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.10.010 · Cited by 729
Smeland, S., Bielack, S. S., Whelan, J., Bernstein, M., Hogendoorn, P., Krailo, M. D., Gorlick, R., Janeway, K. A., Ingleby, F. C., Anninga, J., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.027 · Cited by 704
Current and future therapeutic approaches for osteosarcoma
Harrison, D. J., Geller, D. S., Gill, J. D., Lewis, V. O., & Gorlick, R. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1413939 · Cited by 689
Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.
Meyers, P. A., Heller, G., Healey, J., Huvos, A., Lane, J., Marcove, R., Applewhite, A., Vlamis, V, & Rosen, G. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.5 · Cited by 678
The role and mechanisms of action of microRNAs in cancer drug resistance
Si, W., Shen, J., Zheng, H., & Fan, W. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0587-8 · Cited by 668
Theoleyre, S., Wittrant, Y., Tat, S. K., Fortun, Y., Redini, F., & Heymann, D. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.06.004 · Cited by 663
Mechanisms and insights into drug resistance in cancer
Zahreddine, H., & Borden, K. L. B. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00028 · Cited by 660
O'Connor, O. A., Pro, B., Pinter-Brown, L., Bartlett, N., Popplewell, L., Coiffier, B., Jo Lechowicz, M., Savage, K. J., Shustov, A. R., Gisselbrecht, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.9024 · Cited by 647
Casali, P. G., Bielack, S., Abecassis, N., Aro, H. T., Bauer, S., Biagini, R., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brennan, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy310 · Cited by 617
Cell biology of the osteoclast
Roodman, G. D. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(99)00061-2 · Cited by 571
Osteoimmunology: Interactions of the Bone and Immune System
Lorenzo, J., Horowitz, M., & Choi, Y. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0038 · Cited by 563
Marina, N. M., Smeland, S., Bielack, S. S., Bernstein, M., Jovic, G., Krailo, M. D., Hook, J. M., Arndt, C., van den Berg, H., Brennan, B., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30214-5 · Cited by 551
Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention
Henriksen, P. A. (2018) · Heart · doi:10.1136/heartjnl-2017-312103 · Cited by 536
Perez, E. A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0366 · Cited by 521
Buddingh, E. P., Kuijjer, M. L., Duim, R. A. J., Bürger, H., Agelopoulos, K., Myklebost, O., Serra, M., Mertens, F., Hogendoorn, P. C. W., Lankester, A. C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2047 · Cited by 508
Adjuvant Methotrexate and Citrovorum-Factor Treatment of Osteogenic Sarcoma
Jaffe, N., Frei, E., Traggis, D., & Bishop, Y. (1974) · New England Journal of Medicine · doi:10.1056/nejm197411072911902 · Cited by 483
Perry, J. A., Kiezun, A., Tonzi, P., Van Allen, E. M., Carter, S. L., Baca, S. C., Cowley, G. S., Bhatt, A. S., Rheinbay, E., Pedamallu, C. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419260111 · Cited by 481
HMGB1 release and redox regulates autophagy and apoptosis in cancer cells
Tang, D., Kang, R., Cheh, C.-W., Livesey, K. M., Liang, X., Schapiro, N. E., Benschop, R., Sparvero, L. J., Amoscato, A. A., Tracey, K. J., et al. (2010) · Oncogene · doi:10.1038/onc.2010.261 · Cited by 461
Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?
Anninga, J. K., Gelderblom, H., Fiocco, M., Kroep, J. R., Taminiau, A. H. M., Hogendoorn, P. C. W., & Egeler, R. M. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.05.030 · Cited by 456
Cell cycle-mediated drug resistance: an emerging concept in cancer therapy.
Shah, M. A., & Schwartz, G. K. (2001) · PubMed · Cited by 450
Lipshultz, S. E., Scully, R. E., Lipsitz, S. R., Sallan, S. E., Silverman, L. B., Miller, T. L., Barry, E. V., Asselin, B. L., Athale, U., Clavell, L. A., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70204-7 · Cited by 446
Ferrari, S., Smeland, S., Mercuri, M., Bertoni, F., Longhi, A., Ruggieri, P., Alvegard, T. A., Picci, P., Capanna, R., Bernini, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.5785 · Cited by 435
Soria, J.-C., Felip, E., Cobo, M., Lu, S., Syrigos, K., Lee, K. H., Göker, E., Georgoulias, V., Li, W., Isla, D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00006-6 · Cited by 433
Bielack, S. S., Smeland, S., Whelan, J. S., Marina, N., Jovic, G., Hook, J. M., Krailo, M. D., Gebhardt, M., Pápai, Z., Meyer, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0734 · Cited by 422
Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition.
Hansen, M. F., Koufos, A., Gallie, B. L., Phillips, R. A., Fodstad, O., Brøgger, A., Gedde-Dahl, T., & Cavenee, W. K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.18.6216 · Cited by 415
Devita, V. T., Young, R. C., & Canellos, G. P. (1975) · Cancer · doi:10.1002/1097-0142(197501)35:1<98::aid-cncr2820350115>3.0.co;2-b · Cited by 411
Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells
Song, B., Wang, Y., Xi, Y., Kudo, K., Bruheim, S., Botchkina, G. I., Gavin, E., Wan, Y., Formentini, A., Kornmann, M., et al. (2009) · Oncogene · doi:10.1038/onc.2009.274 · Cited by 410
Expression of P-Glycoprotein in High-Grade Osteosarcomas in Relation to Clinical Outcome
Baldini, N., Scotlandi, K., Barbanti-Bròdano, G., Manara, M. C., Maurici, D., Bacci, G., Bertoni, F., Picci, P., Sottili, S., Campanacci, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511233332103 · Cited by 399
Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response
Fucikova, J., Kralikova, P., Fialova, A., Brtnicky, T., Rob, L., Bartunkova, J., & Špíšek, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0950 · Cited by 392
Chan, C.-H., Morrow, J. K., Li, C.-F., Gao, Y., Jin, G., Moten, A., Stagg, L. J., Ladbury, J. E., Cai, Z., Xu, D., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.048 · Cited by 391
M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis
Kubota, Y., Takubo, K., Shimizu, T., Ohno, H., Kishi, K., Shibuya, M., Saya, H., & Suda, T. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081605 · Cited by 388
Souhami, R. L., Craft, A. W., Van der Eijken, J. W., Nooij, M., Spooner, D., Bramwell, V. H., Wierzbicki, R., Malcolm, A. J., Kirkpatrick, A., Uscinska, B. M., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02307-6 · Cited by 383
Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss
Brock, P. R., Maibach, R., Childs, M., Rajput, K., Roebuck, D., Sullivan, M. J., Laithier, V., Ronghe, M., Dall’Igna, P., Hiyama, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801109 · Cited by 380
Chemotherapy resistance in osteosarcoma: current challenges and future directions
Chou, A. J., & Gorlick, R. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.7.1075 · Cited by 377
Hemann, M. T., & Lowe, S. W. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401962 · Cited by 370
Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone.
Roodman, G. D., Kurihara, N., Ohsaki, Y., Kukita, A., Hosking, D., Demulder, A., Smith, J. F., & Singer, F. R. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115584 · Cited by 366
Grignani, G., Palmerini, E., Dileo, P., Asaftei, S. D., D’Ambrosio, L., Pignochino, Y., Mercuri, M., Picci, P., Fagioli, F., Casali, P. G., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr151 · Cited by 359
Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose
Li, Y., Womer, R. B., & Silber, J. H. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.08.009 · Cited by 358
Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency
Kovac, M., Blattmann, C., Ribi, S., Smida, J., Mueller, N. S., Engert, F., Castro-Giner, F., Weischenfeldt, J., Kovacova, M., Krieg, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms9940 · Cited by 353
Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study.
Winkler, K., Beron, G., Kotz, R., Salzer-Kuntschik, M., Beck, J., Beck, W., Brandeis, W., Ebell, W., Erttmann, R., & Göbel, U. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.6.617 · Cited by 345
Grignani, G., Palmerini, E., Ferraresi, V., D'Ambrosio, L., Bertulli, R., Asaftei, S. D., Tamburini, A., Pignochino, Y., Sangiolo, D., Marchesi, E., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71136-2 · Cited by 340
Mross, K., Frost, A., Steinbild, S., Hedbom, S., Büchert, M., Fasol, U., Unger, C., Krätzschmar, J., Heinig, R., Boix, O., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1900 · Cited by 335
Whelan, J. S., Bielack, S. S., Marina, N., Smeland, S., Jovic, G., Hook, J. M., Krailo, M., Anninga, J., Butterfass-Bahloul, T., Böhling, T., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu526 · Cited by 333
Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors
Merchant, M. S., Wright, M., Baird, K., Wexler, L. H., Rodriguez-Galindo, C., Bernstein, D., Delbrook, C., Lodish, M., Bishop, R., Wolchok, J. D., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0491 · Cited by 331
Duffaud, F., Mir, O., Boudou-Rouquette, P., Piperno-Neumann, S., Penel, N., Bompas, E., Delcambre, C., Kalbacher, E., Italiano, A., Collard, O., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30742-3 · Cited by 331
Italiano, A., Mir, O., Mathoulin-Pelissier, S., Penel, N., Piperno-Neumann, S., Bompas, E., Chevreau, C., Duffaud, F., Entz-Werlé, N., Saada, E., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30825-3 · Cited by 326
Amputation and Adriamycin in Primary Osteosarcoma
Cortes, E. P., Holland, J. F., Wang, J. J., Sinks, L. F., Blom, J., Senn, H., Bank, A., & Glidewell, O. (1974) · New England Journal of Medicine · doi:10.1056/nejm197411072911903 · Cited by 317
Bramwell, V. H., Burgers, M., Sneath, R., Souhami, R., van Oosterom, A. T., Voûte, P. A., Rouesse, J., Spooner, D., Craft, A. W., & Somers, R. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.10.1579 · Cited by 313
HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma
Xiao, X., Wang, W., Li, Y., Yang, D., Li, X., Shen, C., Liu, Y., Ke, X., Guo, S., & Guo, Z. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0880-6 · Cited by 311
T cell–induced CSF1 promotes melanoma resistance to PD1 blockade
Neubert, N. J., Schmittnaegel, M., Bordry, N., Nassiri, S., Wald, N., Martignier, C., Tillé, L., Homicsko, K., Damsky, W., Maby-El Hajjami, H., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan3311 · Cited by 308
Bone Cancer: Diagnosis and Treatment Principles.
Ferguson, J. L., & Turner, S. P. (2018) · PubMed · Cited by 307
(2000) · PubMed · Cited by 304
Expression of HER2/erb B-2 Correlates With Survival in Osteosarcoma
Gorlick, R., Huvos, A. G., Heller, G., Aledo, A., Beardsley, G. P., Healey, J. H., & Meyers, P. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2781 · Cited by 303
Stiller, C. A., Bielack, S. S., Jundt, G., & Steliarova-Foucher, E. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.05.015 · Cited by 283
The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target
Fishel, M. L., & Kelley, M. R. (2007) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2007.04.005 · Cited by 278
HMGB1 Promotes Drug Resistance in Osteosarcoma
Huang, J., Ni, J., Liu, K., Yu, Y., Xie, M., Kang, R., Vernon, P., Cao, L., & Tang, D. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2001 · Cited by 275
Swain, S. M., Whaley, F. S., Gerber, M. C., Ewer, M. S., Bianchine, J. R., & Gams, R. A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1333 · Cited by 269
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
Davis, L. E., Bolejack, V., Ryan, C. W., Ganjoo, K. N., Loggers, E. T., Chawla, S., Agulnik, M., Livingston, M. B., Reed, D., Keedy, V., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02374 · Cited by 268 · cited 2×
“Regorafenib, a multikinase inhibitor with broader activity than sorafenib, led to reduced disease progression [245,246]”
BackgroundKoirala, P., Roth, M. E., Gill, J., Piperdi, S., Chinai, J. M., Geller, D. S., Hoang, B. H., Park, A., Fremed, M. A., Zang, X., et al. (2016) · Scientific Reports · doi:10.1038/srep30093 · Cited by 267
Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells
Song, B., Wang, Y., Titmus, M. A., Botchkina, G., Formentini, A., Kornmann, M., & Ju, J. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-96 · Cited by 265
Gibson, T. M., Mostoufi-Moab, S., Stratton, K. L., Leisenring, W. M., Barnea, D., Chow, E. J., Donaldson, S. S., Howell, R. M., Hudson, M. M., Mahajan, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30537-0 · Cited by 265
Immuno-genomic landscape of osteosarcoma
Wu, C.-C., Beird, H. C., Andrew Livingston, J., Advani, S., Mitra, A., Cao, S., Reuben, A., Ingram, D., Wang, W.-L., Ju, Z., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14646-w · Cited by 251
Bisogno, G., De Salvo, G. L., Bergeron, C., Gallego Melcón, S., Merks, J. H., Kelsey, A., Martelli, H., Minard-Colin, V., Orbach, D., Glosli, H., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30617-5 · Cited by 251
Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells
Basu-Roy, U., Bayin, N. S., Rattanakorn, K., Han, E., Placantonakis, D. G., Mansukhani, A., & Basilico, C. (2015) · Nature Communications · doi:10.1038/ncomms7411 · Cited by 247
Ebb, D., Meyers, P., Grier, H., Bernstein, M., Gorlick, R., Lipshultz, S. E., Krailo, M., Devidas, M., Barkauskas, D. A., Siegal, G. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4546 · Cited by 243
Novel Insights and Therapeutic Interventions for Pediatric Osteosarcoma
Kager, L., Tamamyan, G., & Bielack, S. (2017) · Future Oncology · doi:10.2217/fon-2016-0261 · Cited by 242
Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape
Osipov, A., Saung, M. T., Zheng, L., & Murphy, A. G. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0667-0 · Cited by 241
Dixon, K. H., Lanpher, B. C., Chiu, J., Kelley, K., & Cowan, K. H. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42301-5 · Cited by 240
Moriarity, B. S., Otto, G. M., Rahrmann, E. P., Rathe, S. K., Wolf, N. K., Weg, M. T., Manlove, L. A., LaRue, R. S., Temiz, N. A., Molyneux, S. D., et al. (2015) · Nature Genetics · doi:10.1038/ng.3293 · Cited by 240
Ontogeny of Tumor-Associated Macrophages
Laviron, M., & Boissonnas, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01799 · Cited by 239
Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas
Basu-Roy, U., Seo, E., Ramanathapuram, L., Rapp, T. B., Perry, J. A., Orkin, S. H., Mansukhani, A., & Basilico, C. (2012) · Oncogene · doi:10.1038/onc.2011.405 · Cited by 238
Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects
Janeway, K. A., & Grier, H. E. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70062-0 · Cited by 234
Heymann, M.-F., Lézot, F., & Heymann, D. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.10.011 · Cited by 233
Cells of origin in osteosarcoma: Mesenchymal stem cells or osteoblast committed cells?
Mutsaers, A. J., & Walkley, C. R. (2014) · Bone · doi:10.1016/j.bone.2014.02.003 · Cited by 233
Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumours
London, C., Mathie, T., Stingle, N., Clifford, C., Haney, S., Klein, M. K., Beaver, L., Vickery, K., Vail, D. M., Hershey, B., et al. (2012) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2011.00275.x · Cited by 231
Piperno-Neumann, S., Le Deley, M.-C., Rédini, F., Pacquement, H., Marec-Bérard, P., Petit, P., Brisse, H., Lervat, C., Gentet, J.-C., Entz-Werlé, N., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30096-1 · Cited by 219
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
Paoluzzi, L., Cacavio, A., Ghesani, M., Karambelkar, A., Rapkiewicz, A., Weber, J., & Rosen, G. (2016) · Clinical Sarcoma Research · doi:10.1186/s13569-016-0064-0 · Cited by 218
An update on chemotherapy for osteosarcoma
Ferrari, S., & Serra, M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1102226 · Cited by 213
Terminal osteoblast differentiation, mediated by runx2 and p27 KIP1, is disrupted in osteosarcoma
Thomas, D. M., Johnson, S. A., Sims, N. A., Trivett, M. K., Slavin, J. L., Rubin, B. P., Waring, P., McArthur, G. A., Walkley, C. R., Holloway, A. J., et al. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200409187 · Cited by 208
Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation
Jin, S., Gorfajn, B., Faircloth, G., & Scotto, K. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6775 · Cited by 206
Smith, M. A., Ungerleider, R. S., Horowitz, M. E., & Simon, R. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.20.1460 · Cited by 202
Laoui, D., Van Overmeire, E., De Baetselier, P., Van Ginderachter, J. A., & Raes, G. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00489 · Cited by 200
Ségaliny, A. I., Mohamadi, A., Dizier, B., Lokajczyk, A., Brion, R., Lanel, R., Amiaud, J., Charrier, C., Boisson‐Vidal, C., & Heymann, D. (2015) · International Journal of Cancer · doi:10.1002/ijc.29376 · Cited by 199
Pappo, A. S., Vassal, G., Crowley, J. J., Bolejack, V., Hogendoorn, P. C. W., Chugh, R., Ladanyi, M., Grippo, J. F., Dall, G., Staddon, A. P., et al. (2014) · Cancer · doi:10.1002/cncr.28728 · Cited by 197
Overholtzer, M., Rao, P. H., Favis, R., Lu, X.-Y., Elowitz, M. B., Barany, F., Ladanyi, M., Gorlick, R., & Levine, A. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1934852100 · Cited by 193
Ferrari, S., Ruggieri, P., Cefalo, G., Tamburini, A., Capanna, R., Fagioli, F., Comandone, A., Bertulli, R., Bisogno, G., Palmerini, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4420 · Cited by 192
Lagmay, J. P., Krailo, M. D., Dang, H., Kim, A., Hawkins, D. S., Beaty, O., Widemann, B. C., Zwerdling, T., Bomgaars, L., Langevin, A.-M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.5381 · Cited by 190
Yardley, D. A., Weaver, R., Melisko, M. E., Saleh, M. N., Arena, F. P., Forero, A., Cigler, T., Stopeck, A., Citrin, D., Oliff, I., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2959 · Cited by 190
Cortes, E. P. (1972) · JAMA · doi:10.1001/jama.1972.03200230020005 · Cited by 183
Pignochino, Y., Grignani, G., Cavalloni, G., Motta, M., Tapparo, M., Bruno, S., Bottos, A., Gammaitoni, L., Migliardi, G., Camussi, G., et al. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-118 · Cited by 180
Gomez-Brouchet, A., Illac, C., Gilhodes, J., Bouvier, C., Aubert, S., Guinebretiere, J.-M., Marie, B., Larousserie, F., Entz-Werlé, N., de Pinieux, G., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1331193 · Cited by 179
Methotrexate pharmacokinetics and prognosis in osteosarcoma.
Graf, N., Winkler, K., Betlemovic, M., Fuchs, N., & Bode, U. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.7.1443 · Cited by 176
Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both Topoisomerase II isoforms
Deng, S., Yan, T., Jendrny, C., Nemecek, A., Vincetic, M., Gödtel-Armbrust, U., & Wojnowski, L. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-842 · Cited by 176
Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma
Dumars, C., Ngyuen, J.-M., Gaultier, A., Lanel, R., Corradini, N., Gouin, F., Heymann, D., & Heymann, M.-F. (2016) · Oncotarget · doi:10.18632/oncotarget.13055 · Cited by 174
Macrophages and skeletal health
Michalski, M. N., & McCauley, L. K. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.017 · Cited by 172
Gains and losses of DNA sequences in osteosarcomas by comparative genomic hybridization.
Tarkkanen, M., Karhu, R., Kallioniemi, A. H., et al. (1995) · PubMed · Cited by 171
Transferrin receptor 2 is frequently expressed in human cancer cell lines
Calzolari, A., Oliviero, I., Deaglio, S., Mariani, G., Biffoni, M., Sposi, N. M., Malavasi, F., Peschle, C., & Testa, U. (2007) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2007.02.003 · Cited by 171
Cicenas, J., Zalyte, E., Bairoch, A., & Gaudet, P. (2018) · Cancers · doi:10.3390/cancers10030063 · Cited by 171
Zhou, Q., Xian, M., Xiang, S., Xiang, D., Shao, X., Wang, J., Cao, J., Yang, X., Yang, B., Ying, M., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0259 · Cited by 168
Glucocorticoids and chronic inflammation
Straub, R. H., & Cutolo, M. (2016) · Rheumatology · doi:10.1093/rheumatology/kew348 · Cited by 165
Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines
Honoki (2009) · International Journal of Oncology · doi:10.3892/ijo_00000265 · Cited by 163
Le Deley, M.-C., Guinebretière, J.-M., Gentet, J.-C., Pacquement, H., Pichon, F., Marec-Bérard, P., Entz-Werlé, N., Schmitt, C., Brugières, L., Vanel, D., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.10.023 · Cited by 162
Baud'Huin, M., Renault, R., Charrier, C., Riet, A., Moreau, A., Brion, R., Gouin, F., Duplomb, L., & Heymann, D. (2010) · The Journal of Pathology · doi:10.1002/path.2684 · Cited by 159
Han, Q., Shi, H., & Liu, F. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.01.023 · Cited by 159
West, G. W., Weichselbaum, R. W., & Little, J. B. (1980) · PubMed · Cited by 155
Germline TP53 Variants and Susceptibility to Osteosarcoma
Mirabello, L., Yeager, M., Mai, P. L., Gastier-Foster, J. M., Gorlick, R., Khanna, C., Patiño-Garcia, A., Sierrasesúmaga, L., Lecanda, F., Andrulis, I. L., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv101 · Cited by 155
Cancer risks in patients treated with growth hormone in childhood: the SAGhE European cohort study
Swerdlow, A. J., Cooke, R., Beckers, D., Borgström, B., Butler, G., Carel, J.-C., Cianfarani, S., Clayton, P., Coste, J., Deodati, A., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2046 · Cited by 153 · cited 1×
“Furthermore, children treated with GH have been found to have an increased incidence of osteosarcoma [30].”
BackgroundFritzsching, B., Fellenberg, J., Moskovszky, L. E., Sápi, Z., Krenács, T., Machado, I., Poeschl, J., Lehner, B., Szendrői, M., Bosch, A. L., et al. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.990800 · Cited by 153
Mechanisms of methotrexate resistance in osteosarcoma.
Guo, W., Healey, J. H., Meyers, P. A., Ladanyi, M., Huvos, A. G., Bertino, J. R., & Gorlick, R. G. (1999) · PubMed · Cited by 152
Honoki (2010) · Oncology Reports · doi:10.3892/or_00000885 · Cited by 151
Mao, Y., Eißler, N., Blanc, K. L., Johnsen, J. I., Kogner, P., & Kiessling, R. W. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1912 · Cited by 151
Tarkkanen, M., Elomaa, I., BLOMQVIST, C. P., Kivioja, A., Kellokumpu‐Lehtinen, P., B�hling, T., Valle, J., & Knuutila, S. (1999) · International Journal of Cancer · Cited by 150
Post Operative Infection and Increased Survival in Osteosarcoma Patients: Are They Associated?
Jeys, L. M., Grimer, R. J., Carter, S. R., Tillman, R. M., & Abudu, A. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9483-8 · Cited by 145
Windsor, R. E., Strauss, S. J., Kallis, C., Wood, N. E., & Whelan, J. S. (2011) · Cancer · doi:10.1002/cncr.26472 · Cited by 145
Caronia, D., Patiño‐García, A., Milne, R. L., Zalacaín, M., Pita, G., Alonso, M. R., Moreno, L. T., Sierrasesúmaga-Ariznabarreta, L., Benitez, J. J., & González‐Neira, A. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.19 · Cited by 144
Verrecchia, F., & Rédiní, F. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00133 · Cited by 144
Göker, E., Waltham, M. C., Kheradpour, A., Trippett, T. M., Mazumdar, M., Elisseyeff, Y., Schnieders, B., Steinherz, P. G., Tan, C. W., & Berman, E. (1995) · Blood · doi:10.1182/blood.v86.2.677.bloodjournal862677 · Cited by 143
Bacci, G., Ferrari, S., Delépine, N., Bertoni, F., Picci, P., Mercuri, M., Bacchini, P., del Prever, A. B., Tienghi, A., Comandone, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.658 · Cited by 141
Hughes, D. P. M., Thomas, D. G., Giordano, T. J., Baker, L. H., & McDonagh, K. T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3096 · Cited by 140
Recent advances of drug delivery nanocarriers in osteosarcoma treatment
Wang, S., Hu, H.-Z., Qing, X.-C., Zhang, Z., & Shao, Z.-W. (2019) · Journal of Cancer · doi:10.7150/jca.36588 · Cited by 140
Doxorubicin in disseminated osteosarcoma
Cores, E. P. (1972) · JAMA · doi:10.1001/jama.221.10.1132 · Cited by 138
Vijayakumar, S., Liu, G., Rus, I. A., Yao, S., Chen, Y., Akiri, G., Grumolato, L., & Aaronson, S. A. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.010 · Cited by 137
Lee, Y. H., Tokunaga, T., Oshika, Y., Suto, R., Yanagisawa, K., Tomisawa, M., Fukuda, H., Nakano, H., Abe, S., Tateishi, A., et al. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00073-8 · Cited by 136
Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma
Meyers, P. A. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.69 · Cited by 134
Long-Term Evaluation of Ifosfamide-Related Nephrotoxicity in Children
Oberlin, O., Fawaz, O., Rey, A., Niaudet, P., Ridola, V., Orbach, D. H., Bergeron, C., Defachelles, A. S., Gentet, J., Schmitt, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5257 · Cited by 134
Tunggal, J. K., Cowan, D., Shaikh, H., & Tannock, I. F. (1999) · PubMed · Cited by 133
High-Dose Chemotherapy in the Treatment of Relapsed Osteosarcoma: An Italian Sarcoma Group Study
Fagioli, F., Aglietta, M., Tienghi, A., Ferrari, S., del Prever, A. B., Vassallo, E., Palmero, A., Biasin, E., Bacci, G., Picci, P., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.081 · Cited by 133
Acquisition of resistance to antifolates caused by enhanced gamma-glutamyl hydrolase activity.
Rhee, M. S., Wang, Y., Nair, M. G., et al. (1993) · PubMed · Cited by 132
P-glycoprotein Expression: Critical Determinant in the Response to Osteosarcoma Chemotherapy
Chan, H. S. L., Haddad, G., DeBoer, G., Ling, V. W. T., & Grogan, T. M. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.22.1706 · Cited by 132
Sorafenib: key lessons from over 10 years of experience
Escudier, B. J., Worden, F. P., & Kudo, M. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1559058 · Cited by 128
Review of mifamurtide in the treatment of patients with osteosarcoma
Kager, L., Pötschger, U., & Bielack (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s5688 · Cited by 126
Overcoming Glutathione S -Transferase P1–Related Cisplatin Resistance in Osteosarcoma
Pasello, M., Michelacci, F., Scionti, I., Hattinger, C. M., Zuntini, M., Caccuri, A. M., Scotlandi, K., Picci, P., & Serra, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5840 · Cited by 125
Goorin, A. M., Pérez‐Atayde, A. R., Gebhardt, M. C., Andersen, J. W., Wilkinson, R. H., Delorey, M. J., Watts, H. G., Link, M. P., Jaffe, N., & Frei, E. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.8.1178 · Cited by 125
Overexpression of Smad7 Blocks Primary Tumor Growth and Lung Metastasis Development in Osteosarcoma
Lamora, A., Talbot, J., Bougras-Cartron, G., Amiaud, J., Leduc, M., Chesneau, J., Taurelle, J., Stresing, V., Deley, M. L., Heymann, M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3191 · Cited by 124
Nielsen, S. N., Grell, K., Nersting, J., Abrahamsson, J., Lund, B., Kanerva, J. A., Jónsson, Ó. G., Vaitkevičienė, G. E., Pruunsild, K., Hjalgrim, L. L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30154-7 · Cited by 123
Uozaki, H., Horiuchi, H., Ishida, T., Iijima, T., Imamura, T., & Machinami, R. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970615)79:12<2336::aid-cncr7>3.0.co;2-j · Cited by 121
IGF‐1 receptor contributes to the malignant phenotype in human and canine osteosarcoma
MacEwen, E. G., Pastor, J., Kutzke, J., Tsan, R. Z., Kurzman, I. D., Thamm, D. H., Wilson, M., & Radinsky, R. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20046 · Cited by 118
Multiple Drug Resistance in Osteogenic Sarcoma: INT0133 From the Children's Oncology Group
Schwartz, C. L., Gorlick, R. G., Teot, L. A., Krailo, M., Chen, Z., Goorin, A. M., Grier, H. E., Bernstein, M. L., & Meyers, P. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.7776 · Cited by 118
Martins‐Neves, S. R., Lopes, Á. O., do Carmo, A., Paiva, A. A., Simões, P. C. P. S., Abrunhosa, A., & Gomes, C. M. F. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-139 · Cited by 117
The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis
Endo‐Munoz, L., Evdokiou, A., & Saunders, N. A. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.07.003 · Cited by 116
Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program
Maris, J. M., Courtright, J., Houghton, P. J., Morton, C. L., Gorlick, R. G., Kolb, E. A., Lock, R. B., Tajbakhsh, M., Reynolds, C. P., Keir, S. T., et al. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21232 · Cited by 116
Pignochino, Y., Dell’Aglio, C., Basiricò, M., Capozzi, F., Soster, M., Marchiò, S., Bruno, S., Gammaitoni, L., Sangiolo, D., Torchiaro, E., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2293 · Cited by 112
ErbB2 expression is correlated with increased survival of patients with osteosarcoma
Akatsuka, T., Wada, T., Kokai, Y., Kawaguchi, S., Isu, K., Yamashiro, K., Yamashita, T., Sawada, N., Yamawaki, S., & Ishii, S. (2002) · Cancer · doi:10.1002/cncr.10360 · Cited by 112
Cisplatin dose rate as a risk factor for nephrotoxicity in children
Skinner, R., Pearson, A. D. J., English, M., Price, L., Wyllie, R., Coulthard, M., & Craft, A. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.276 · Cited by 112
Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma
Huang, J. X., Liu, K., Yu, Y. P., et al. (2012) · Autophagy · doi:10.4161/auto.8.2.18940 · Cited by 111
Nanoparticle enhanced MRI can monitor macrophage response to CD47 mAb immunotherapy in osteosarcoma
Mohanty, S., Yerneni, K., Theruvath, J. L., Graef, C. M., Nejadnik, H., Lenkov, O. D., Pisani, L. J., Rosenberg, J., Mitra, S. S., Sweet-Cordero, A., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-018-1285-3 · Cited by 109
Li, W., Fan, J., Hochhauser, D., Banerjee, D., Zieliński, Z., Almasan, A., Yin, Y., Kelly, R., Wahl, G. M., & Bertino, J. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.22.10436 · Cited by 108
Cited by
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
Unveiling the mechanisms and challenges of cancer drug resistance
Khan, S. U., Fatima, K., Aisha, S., & Malik, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01302-1 · Cited by 417
Systematic Review of Recurrent Osteosarcoma Systemic Therapy
Gazouli, I., Kyriazoglou, A., Kotsantis, I., Anastasiou, M., Pantazopoulos, A., Prevezanou, M., Chatzidakis, I., Kavourakis, G., Economopoulou, P., Kontogeorgakos, V., et al. (2021) · Cancers · doi:10.3390/cancers13081757 · Cited by 63
Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma
Landuzzi, L., Manara, M. C., Lollini, P.-L., & Scotlandi, K. (2021) · Cells · doi:10.3390/cells10020416 · Cited by 39
Recent Advances in Nanoplatforms for the Treatment of Osteosarcoma
Wu, K., Yu, B., Li, D., Tian, Y., Liu, Y., & Jiang, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.805978 · Cited by 39
Metadata
- Authors
- Lilienthal, I., & Herold, N.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-09-19
- Volume
- 21
- Issue
- 18
- Pages
- 6885
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3087198975
- Cited by
- 283
- References
- 379
- FWCI
- 18.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.